Polycystic ovary syndrome in adolescence

Endocrinologist

Volumn 12, Issue 4, 2002, Pages 333-348

  Baumann, Elizabeth E ^a   Rosenfield, Robert L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIANDROGEN; DEXTRO INOSITOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL; ETHINYLESTRADIOL PLUS ETYNODIOL DIACETATE; ETHINYLESTRADIOL PLUS NORGESTIMATE; GESTAGEN; GLUCOCORTICOID; GLUCOSE; GONADORELIN AGONIST; HYDROXYPROGESTERONE; INOSITOL DERIVATIVE; INSULIN; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; METFORMIN; ORAL ANTIDIABETIC AGENT; ORAL CONTRACEPTIVE AGENT; PIOGLITAZONE; PREDNISONE; PROLACTIN; ROSIGLITAZONE; SEX HORMONE BINDING GLOBULIN; SPIRONOLACTONE; TESTOSTERONE; TETRACOSACTIDE; TROGLITAZONE; UNCLASSIFIED DRUG;

ACNE; ADOLESCENT; ADOLESCENT DISEASE; ALOPECIA; ANOVULATION; CLINICAL FEATURE; CONGENITAL ADRENAL HYPERPLASIA; DEXAMETHASONE SUPPRESSION TEST; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; ECHOGRAPHY; FATIGUE; FEMALE; GENETIC TRAIT; HERMAPHRODITISM; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERKALEMIA; HYPERPROLACTINEMIA; HYPOPHYSIS FUNCTION; INSULIN RESISTANCE; LIVER TOXICITY; METABOLIC DISORDER; METRORRHAGIA; OBESITY; ORAL CONTRACEPTION; OVARY POLYCYSTIC DISEASE; REVIEW; SEX HORMONE DETERMINATION; STEROID 21 MONOOXYGENASE DEFICIENCY; STEROIDOGENESIS;

EID: 0036073073     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019616-200207000-00011     Document Type: Review

References (151)

1. Amenorrhea associated with bilateral polycystic ovaries
2. The polycystic ovary. I. Clinical and histologic features
3. Multifollicular ovaries: Clinical and endocrine features and response to pulsatile gonadotrophin releasing hormone
4. Ultrasound assessment of ovarian stroma hypertrophy in hyperandrogenism and ovulation disorders: Visual analysis versus computerized quantification
5. Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease
6. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion
7. Polycystic ovary syndrome and insulin-resistant hyperinsulinemia
8. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach
9. Polycystic ovary syndrome
10. Ovarian and adrenal function in polycystic ovary syndrome
11. Effect of adrenal and ovarian androgens on type 4 follicles unresponsive to FSH in immature mice
12. 17-Hydroxyprogesterone response to buserelin testing in the polycystic ovary syndrome
13. The polycystic ovary syndrome: Pathogenesis and treatment
14. Polycystic ovarian syndrome: Evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone
15. Insulin receptors in the pituitary gland: Morphological evidence for influence on opioid peptide-synthesizing cells
16. Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells
17. Interactions of insulin-like growth factor-I, insulin and estradiol with GnRH-stimulated luteinizing hormone release from female rat gonadotrophs
18. Role of brain insulin receptor in control of body weight and reproduction
19. IRS-2 pathways integrate female reproduction and energy homeostasis
20. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome
21. Inappropriate gonadotropin secretion in polycystic ovary syndrome: Influence of adiposity
22. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome
23. Detection of functional ovarian hyperandrogenism in women with androgen excess
24. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome
25. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: Evidence from GnRH agonist and human chorionic gonadotropin stimulation testing
26. Hypersecretion of androstenedione by isolated theca cells from polycystic ovaries
27. Diagnosis of polycystic ovary syndrome in adolescence. Comparison of adolescent and adult hyperandrogenism
28. Studies of the nature of 17-hydroxyprogesterone hyperresponsiveness to gonadotropin releasing hormone agonist challenge in functional ovarian hyperandrogenism
29. Differential activity of the cytochrome P450 17α-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells
30. Luteinizing hormone receptor, steroidogenesis acute regulatory protein, and steroidogenic enzyme messenger ribonucleic acids are overexpressed in thecal and granulosa cells from polycystic ovaries
31. Estradiol production by granulosa cells of normal and polycystic ovaries: Relationship to menstrual cycle history and concentrations of gonadotropins and sex steroids in follicular fluid
32. Aromatase mRNA expression in individual follicles from polycystic ovaries
33. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: An analysis of 109 pregnancies in 225 women
34. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome
35. Effect of follicle-stimulating hormone on ovarian androgen production in a woman with isolated follicle-stimulating hormone deficiency
36. Heterodimers and homodimers of inhibin subunits have different paracrine action in the modulation of luteinizing hormone-stimulated androgen biosynthesis
37. Effect of recombinant activin on androgen synthesis in cultured human thecal cells
38. Control of inhibin production by human granulosa cells
39. Inhibin production by bovine ovarian tissues in vitro and its regulation by androgens
40. Circulating follistatin concentrations are higher and activin concentrations are lower in polycystic ovarian syndrome
41. Serum α-inhibin levels in polycystic ovary syndrome: Relationship to the serum androstenedione level
42. Inhibin A and inhibin B in women with polycystic ovarian syndrome during treatment with FSH to induce mono-ovulation
43. The rise of estradiol and inhibin B after acute stimulation with follicle-stimulating hormone predict the follicle cohort size in women with polycystic ovary syndrome, regularly menstruating women with polycystic ovaries, and regularly menstruating women with normal ovaries
44. Intraadrenal interactions in the regulation of adrenocortical steroidogenesis
45. Neuroimmunoregulation of androgens in the adrenal gland and the skin
46. Use of insulin-sensitizing agents in patients with polycystic ovary syndrome
47. Puberty and polycystic ovarian syndrome: The insulin/insulin-like growth factor I hypothesis
48. Metabolic lessons from the study of young adolescents with polycystic ovary syndrome-is insulin, indeed, the culprit?
49. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome
50. Regulation of beta-cell function in vivo: From health to disease
51. Acanthosis nigricans, insulin action, and hyperandrogenism: Clinical, histological, and biochemical findings
52. The prevalence of polycystic ovaries in women with type 2 diabetes mellitus
53. Insulin-mediated pseudoacromegaly: Clinical and biochemical characterization of a syndrome of selective insulin resistance
54. Selective insulin resistance in the polycystic ovary syndrome
55. Phosphatidyl-inositol-3 kinase-independent insulin action pathway(s) in the human ovary
56. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS)
57. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system
58. Serine phosphorylation of human P450c17 increases 17, 20-lyase activity: Implications for adrenarche and the polycystic ovary syndrome
59. Current concepts of polycystic ovary syndrome
60. Genetics of polycystic ovary syndrome
61. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome
62. Variants of the type II 3 betahydroxysteroid-dehydrogenase gene in children with premature pubic hair and hyperandrogenic adolescents
63. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing
64. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP 17
65. Polycystic ovaries are inherited as an autosomal dominant trait: Analysis of 29 polycystic ovary syndrome and 10 control families
66. Evidence for a single gene effect causing polycystic ovaries and male pattern baldness
67. Hyperandrogenism and manifesting heterozygotes for 21-hydroxylase deficiency
68. Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism: Relation to reduced fetal growth
69. Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency
70. Ovarian hyperandrogenism as a result of congenital adrenal virilizing disorders: Evidence for perinatal masculinization of neuroendocrine function in women
71. Pituitary-ovarian responses to leuprolide acetate testing in patients with congenital adrenal hyperplasia due to 21 hydroxylase deficiency
72. Insights into the development of polycystic ovary syndrome (PCOS) from studies of prenatally androgenized female Rhesus monkeys
73. In utero exposure of female lambs to testosterone reduces the sensitivity of the gonadotropin-releasing hormone neuronal network to inhibition by progesterone
74. Relation of functional ovarian hyperandrogenism to non-insulin dependent diabetes mellitus
75. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome
76. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: A retrospective cohort study
77. Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome
78. Evidence for association of polycystic ovary syndrome in Caucasian women with a marker at the insulin receptor gene locus
79. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestogen treatment
80. High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus
81. Ovarian 17 alpha-hydroxyprogesterone responses to GnRH analog testing in oligomenorrheic insulin-dependent diabetic adolescents
82. Low grade chronic inflammation in women with polycystic ovarian syndrome
83. Role of hormones in pilosebaceous unit development
84. Hyperhidrosis as the only manifestation of hyperandrogenism in an adolescent girl
85. The SAHA Syndrome
86. Idiopathic hirsutism
87. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism
88. Anovulation after precocious pubarche: Early markers and time course in adolescence
89. Girls diagnosed with premature pubarche show an exaggerated ovarian androgen synthesis from the early stages of puberty: Evidence from gonadotropin-releasing hormone agonist testing
90. The morphology of the prepubertal ovary: Relationship to the polycystic ovary syndrome
91. Standards for ovarian volume in childhood and puberty
92. Hyperandrogenism during puberty and adolescence, and its relationship to reproductive function in the adult female
93. The prognosis for adolescents with menstrual abnormalities
94. Endocrinologic features of oligomenorrheic adolescent girls
95. Menstrual irregularities in adolescents: Hormonal pattern and ovarian morphology
96. Postmenarchal evolution of endocrine pattern and ovarian aspects in adolescents with menstrual irregularities
97. Relation of acanthosis nigricans to hyperinsulinemia and insulin sensitivity in overweight African American and white children
98. Obesity, lipids, cardiovascular risk, and androgen excess
99. Fetal nutrition and adult disease
100. Impaired regulation of glucose transporter 4 gene expression in insulin resistance associated with in utero undernutrition
101. Postpubertal outcome in girls diagnosed of premature pubarche during childhood: Increased frequency of functional ovarian hyperandrogenism
102. Polycystic ovary syndrome after precocious pubarche: Ontogeny of the low-birthweight effect
103. Are adrenal and ovarian function normal in true precocious puberty?
104. Pseudocushing syndrome and pseudoacromegalic gigantism associated with insulin resistant hyperinsulinism as childhood precursors of polycystic ovary syndrome
105. Longitudinal change of sonographic ovarian aspects and endocrine parameters in irregular cycles of adolescence
106. Endocrine determinants of fertility: Serum androgen concentrations during follow-up of adolescents into the third decade of life
107. Longitudinal evaluation of the different gonadotropin pulsatile patterns in anovulatory cycles of young girls
108. Adult outcome of hyperandrogenic adolescence
109. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation
110. Glucose intolerance in obese adolescents with polycystic ovary syndrome: Roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease
111. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome
112. Lipids and lipoprotein subfractions in women with PCOS: Relationship to metabolic and endocrine parameters
113. Smaller LDL particle size in women with polycystic ovary syndrome compared to controls
114. The metabolic syndrome, LDL particle size, and atherosclerosis: The Atherosclerosis and Insulin Resistance (AIR) study
115. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women
116. Role of exogenous and endogenous hormones in endometrial cancer: Review of the evidence and research perspectives
117. Menstrual irregularity in women with acromegaly
118. Ovarian hyperthecosis in the setting of portal hypertension
119. Ovarian and adrenal steroidogenesis in a virilized patient with gonadotropin-resistant ovaries and hilus cell hyperplasia
120. Polycystic ovarian syndrome-relationship to epilepsy and antiepileptic drug therapy
121. Amenorrhea related to progestin excess in congenital adrenal hyperplasia
122. Elevated progesterone (P) in congenital adrenal hyperplasia (CAH)1 alters LH secretory dynamics
123. Multiple androgenic abnormalities, including elevated free testosterone, in hyperprolactinemic women
124. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids
125. Apparent cortisone reductase deficiency: A functional defect in 11 beta-hydroxysteroid dehydrogenase type 1
126. How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome?
127. Pituitary tumors associated with hyperprolactinemia and polycystic ovary disease
128. Plasma testosterone binding globulin and indexes of the concentration of unbound androgens in normal and hirsute subjects
129. Androgen parameters and their correlation with body weight in one hundred thirty-eight women thought to have hyperandrogenism
130. A direct effect of hyperinsulinemia on serum sex hormone binding globulin levels in obese women with the polycystic ovary syndrome
131. Diagnosis and therapy of hyperandrogenism
132. Hyperandrogenic chronic anovulation
133. Evaluation and treatment of hirsute women
134. The ovary and female maturation
135. Steroid 21-hydroxylase deficiency (congenital adrenal hyperplasia)
136. Congenital adrenal hyperplasia
137. Use of leuprolide acetate response patterns in the early diagnosis of pubertal disorders: Comparison with the gonadotropin-releasing hormone test
138. Next generation of contraception: Oral contraceptives in the 1990s
139. Drospirenone: Pharmacology and pharmacokinetics of a unique progestogen
140. Oral contraceptives and the risk of venous thrombosis
141. Hormonal effects of flutamide in young women with polycystic ovary syndrome
142. Adrenal suppression, evaluated by a low dose adrenocorticotropin test, and growth in asthmatic children treated with inhaled steroids
143. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level
144. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: Effect of flutamide
145. Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in women with polycystic ovary syndrome
146. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: A multicenter, double blind, placebo-controlled trial
147. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome
148. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche
149. Metformin in non-alcoholic steatohepatitis
150. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: Amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance
151. Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3 beta-hydroxysteroid dehydrogenase